Skip to main content
Top
Published in: Techniques in Coloproctology 10/2020

01-10-2020 | Peritonectomy | Multimedia Article

Complete laparoscopic pelvic peritonectomy plus hyperthermic intraperitoneal chemotherapy

Authors: A. Arjona-Sánchez, D. Cortés-Guiral, M. Duran-Martínez, P. Villarejo-Campos, J. M. Sánchez-Hidalgo, A. Casado-Adam, L. Rodriguez-Ortiz, A. Romero-Ruiz, B. Rufian-Andujar, E. Espinosa-Redondo, F. Valenzuela-Molina, S. Rufián-Peña, J. Briceño-Delgado

Published in: Techniques in Coloproctology | Issue 10/2020

Login to get access

Abstract

Background

The aim of our study was to present the technique for, and early results of complete laparoscopic pelvic peritonectomy (LPP) plus hyperthermic intraperitoneal chemotherapy (HIPEC).

Methods

We conducted a study on consecutive patients who had LPP for limited peritoneal carcinomatosis (peritoneal carcinomatosis index < 10) from ovarian cancer, colon cancer and benign multicystic mesothelioma, from January 2017 to November 2019 at 2 referral centers in Spain. Perioperative, pathologic, 30-day major morbidity and mortality characteristics were analyzed. The surgical technique is shown in the attached video.

Results

Twelve LPP + HIPEC were performed. Complete cytoreduction was achieved in 100% of the patients, the median duration of the operation was 450 min (range 360–600 min). There were 2 cases (16%) of IIIa morbidity (trocar hernia and pleural effusion), and no mortality. The median length of hospital stay was 5.5 days (range 4–10 days). The median length of follow-up was 10 months (range 2–30 months). There was a recurrence at the splenic hilum in 1 patient which was treated by laparoscopic splenectomy and one nodal recurrence at 13 months while all other patients are alive and free of disease at last follow-up.

Conclusions

This is the first technical video of a minimally invasive approach for complete pelvic peritonectomy plus omentectomy associated with HIPEC. For highly selected patients, this procedure presents a feasible and safe alternative to the maximally invasive approach.
Appendix
Available only for authorised users
Literature
1.
go back to reference Foster JM, Sleightholm R, Patel A et al (2019) Morbidity and mortality rates following cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy compared with other high-risk surgical oncology procedures. JAMA Netw Open 2(1):e186847CrossRef Foster JM, Sleightholm R, Patel A et al (2019) Morbidity and mortality rates following cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy compared with other high-risk surgical oncology procedures. JAMA Netw Open 2(1):e186847CrossRef
2.
go back to reference Sugarbaker PH (2013) Cytoreductive surgery & perioperative chemotherapy for peritoneal surface malignancy: textbook and video atlas. PSOGI 1:1–22 Sugarbaker PH (2013) Cytoreductive surgery & perioperative chemotherapy for peritoneal surface malignancy: textbook and video atlas. PSOGI 1:1–22
3.
go back to reference Chua TC, Yan TD, Saxena A, Morris DL (2009) Should the treatment of peritoneal carcinomatosis by cytoreductive surgery andhyperthermic intraperitoneal chemotherapy still be regarded as a highly morbid procedure?: a systematic review of morbidity and mortality. Ann Surg 249:900–907CrossRef Chua TC, Yan TD, Saxena A, Morris DL (2009) Should the treatment of peritoneal carcinomatosis by cytoreductive surgery andhyperthermic intraperitoneal chemotherapy still be regarded as a highly morbid procedure?: a systematic review of morbidity and mortality. Ann Surg 249:900–907CrossRef
4.
go back to reference Esquivel J, Averbach A, Chua TC (2011) Laparoscopic cytoreductivesurgery and hyperthermic intraperitoneal chemotherapyin patients with limited peritoneal surface malignancies: feasibility, morbidity and outcome in an early experience. Ann Surg 253:764–768CrossRef Esquivel J, Averbach A, Chua TC (2011) Laparoscopic cytoreductivesurgery and hyperthermic intraperitoneal chemotherapyin patients with limited peritoneal surface malignancies: feasibility, morbidity and outcome in an early experience. Ann Surg 253:764–768CrossRef
5.
go back to reference Passot G, Bakrin N, Isaac S, Decullier E, Gilly FN, Glehen O, Cotte E (2013) Postoperative outcomes of laparoscopic vs open cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for treatment of peritoneal surface malignancies. Eur J Surg Oncol 40:957–962CrossRef Passot G, Bakrin N, Isaac S, Decullier E, Gilly FN, Glehen O, Cotte E (2013) Postoperative outcomes of laparoscopic vs open cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for treatment of peritoneal surface malignancies. Eur J Surg Oncol 40:957–962CrossRef
6.
go back to reference Arjona-Sanchez A, Esquivel J, Glehen O et al (2019) A minimally invasive approach for peritonectomy procedures and hyperthermic intraperitoneal chemotherapy (HIPEC) in limited peritoneal carcinomatosis: The American Society of Peritoneal Surface Malignancies (ASPSM) multi-institution analysis. Surg Endosc 33(3):854–860CrossRef Arjona-Sanchez A, Esquivel J, Glehen O et al (2019) A minimally invasive approach for peritonectomy procedures and hyperthermic intraperitoneal chemotherapy (HIPEC) in limited peritoneal carcinomatosis: The American Society of Peritoneal Surface Malignancies (ASPSM) multi-institution analysis. Surg Endosc 33(3):854–860CrossRef
7.
go back to reference Arjona-Sanchez A, Rufian-Peña S, Sanchez-Hidalgo JM, Casado-Adam A, Cosano-Alvarez A, Briceño-Delgado J (2018) Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy (HIPEC) by minimally invasive approach, an initial experience. World J Surg 42(10):3120–3124CrossRef Arjona-Sanchez A, Rufian-Peña S, Sanchez-Hidalgo JM, Casado-Adam A, Cosano-Alvarez A, Briceño-Delgado J (2018) Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy (HIPEC) by minimally invasive approach, an initial experience. World J Surg 42(10):3120–3124CrossRef
8.
go back to reference Arjona-Sanchez A, Durán M, Sanchez Hidalgo JM, Rufian Peña S (2019) Peritoneal carcinomatosis from ovarian carcinoma treated by interval laparoscopic complete cytoreduction and HIPEC with extraction through natural orifice. Surg Oncol 31:14–15CrossRef Arjona-Sanchez A, Durán M, Sanchez Hidalgo JM, Rufian Peña S (2019) Peritoneal carcinomatosis from ovarian carcinoma treated by interval laparoscopic complete cytoreduction and HIPEC with extraction through natural orifice. Surg Oncol 31:14–15CrossRef
9.
go back to reference Gallotta V, Ghezzi F, Vizza E, Fagotti A, Ceccaroni M, Fanfani F, Chiantera V, Ercoli A, Rossitto C, Conte C, Uccella S, Corrado G, Scambia G, Ferrandina G (2016) Laparoscopic management of ovarian cancer patients with localized carcinomatosis and lymph node metastases: results of a retrospective multi-institutional series. J Min Invasive Gynecol 23(4):590–596CrossRef Gallotta V, Ghezzi F, Vizza E, Fagotti A, Ceccaroni M, Fanfani F, Chiantera V, Ercoli A, Rossitto C, Conte C, Uccella S, Corrado G, Scambia G, Ferrandina G (2016) Laparoscopic management of ovarian cancer patients with localized carcinomatosis and lymph node metastases: results of a retrospective multi-institutional series. J Min Invasive Gynecol 23(4):590–596CrossRef
10.
go back to reference Harter P, Sehouli J, Lorusso D et al (2019) A randomized trial of lymphadenectomy in patients with advanced ovarian neoplasms. N Engl J Med 380:822–832CrossRef Harter P, Sehouli J, Lorusso D et al (2019) A randomized trial of lymphadenectomy in patients with advanced ovarian neoplasms. N Engl J Med 380:822–832CrossRef
11.
go back to reference Sánchez-Hidalgo JM, Rodríguez-Ortiz L, Arjona-Sánchez A et al (2019) Colorectal peritoneal metastases: optimal management review. World J Gastroenterol 25(27):3484–3502CrossRef Sánchez-Hidalgo JM, Rodríguez-Ortiz L, Arjona-Sánchez A et al (2019) Colorectal peritoneal metastases: optimal management review. World J Gastroenterol 25(27):3484–3502CrossRef
12.
go back to reference Quenet F, Elias D, Roca L et al (2018) A UNICANCER phase III trial of hyperthermic intra-peritoneal chemotherapy (HIPEC) for colorectal peritoneal carcinomatosis (PC): PRODIGE 7. J Clin Oncol 36:3503CrossRef Quenet F, Elias D, Roca L et al (2018) A UNICANCER phase III trial of hyperthermic intra-peritoneal chemotherapy (HIPEC) for colorectal peritoneal carcinomatosis (PC): PRODIGE 7. J Clin Oncol 36:3503CrossRef
13.
go back to reference Prada-Villaverde A, Esquivel J, Lowy AM et al (2014) The American Society of Peritoneal Surface Malignancies Evaluation of HIPEC with mitomycin C versus oxaliplatin in 539 patients with colon cancer undergoing a complete cytoreductive surgery. J Surg Oncol 110(7):779–785CrossRef Prada-Villaverde A, Esquivel J, Lowy AM et al (2014) The American Society of Peritoneal Surface Malignancies Evaluation of HIPEC with mitomycin C versus oxaliplatin in 539 patients with colon cancer undergoing a complete cytoreductive surgery. J Surg Oncol 110(7):779–785CrossRef
Metadata
Title
Complete laparoscopic pelvic peritonectomy plus hyperthermic intraperitoneal chemotherapy
Authors
A. Arjona-Sánchez
D. Cortés-Guiral
M. Duran-Martínez
P. Villarejo-Campos
J. M. Sánchez-Hidalgo
A. Casado-Adam
L. Rodriguez-Ortiz
A. Romero-Ruiz
B. Rufian-Andujar
E. Espinosa-Redondo
F. Valenzuela-Molina
S. Rufián-Peña
J. Briceño-Delgado
Publication date
01-10-2020
Publisher
Springer International Publishing
Published in
Techniques in Coloproctology / Issue 10/2020
Print ISSN: 1123-6337
Electronic ISSN: 1128-045X
DOI
https://doi.org/10.1007/s10151-020-02277-8

Other articles of this Issue 10/2020

Techniques in Coloproctology 10/2020 Go to the issue